Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Azemiglitazone (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms EMMINENCE
- Sponsors Cirius Therapeutics
- 24 Jun 2023 Results assessing the serological extracellular matrixbiomarkers PRO-C3, PRO-C4 and PRO-C6, which serve as surrogates of fibroblast activity, pericellular fibrosis formation and the profi-brotic and proinflammatory fragment endotrophin , presented at the European Association for the Study of the Liver Congress 2023
- 29 Jun 2021 Results assessing Branched-Chain Amino Acid Catabolism(BCAA) from plasma collected from this trial, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2021 Results assessing the novel graph neural network (GNN) approach that combines interpretability with performance for NASH scoring, presented at The International Liver Congress 2021.